Study on Human Bioequivalence of Triprerelin Acetate for Injection

This study tests whether two versions of a hormone-suppressing injection called triptorelin acetate are equivalent in how the body absorbs and processes them (bioequivalence study), in men with prostate cancer who need hormone therapy to lower testosterone. **You may be eligible if...** - You are a male aged 18 or older, weighing at least 50 kg, with a BMI between 19 and 30 - You have prostate cancer confirmed by pathology and are suitable for hormone therapy (androgen deprivation therapy) - You are either new to GnRH-analog treatment, currently receiving stable triptorelin injections, or have previously received GnRH-analog therapy and are suitable to restart - You are in reasonable physical health (ECOG 0–2) **You may NOT be eligible if...** - You have severe organ failure or serious medical conditions - Your prostate cancer is not suitable for hormone treatment - You are unwilling to comply with study requirements Talk to your doctor to see if this trial is right for you.